Conference
Earn CE
Free Samples
Magazine
Subscribe
Videos
Solutions Lab
Macro/Op-Ed
Practice
Science & Tech
Money
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Dental Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Athira Pharma Inc
(NQ:
ATHA
)
3.290
-0.010 (-0.30%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Athira Pharma Inc
< Previous
1
2
3
4
5
6
7
Next >
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
August 01, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024
July 31, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
July 09, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
June 12, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
June 11, 2024
First-in-human, dose escalation study to evaluate safety, tolerability and pharmacokinetics in healthy volunteers with trial completion expected by year-end 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma to Participate in Upcoming June Conferences
May 29, 2024
Management to Highlight Robust Pipeline in Neurodegenerative Diseases with Key Phase 2/3 LIFT-AD Topline Data in Alzheimer’s Disease on Track for Second Half of 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
May 17, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
May 15, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma to Participate in Upcoming May Conferences
May 02, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
April 15, 2024
Experienced clinical development leader with a strong track record of advancing therapeutics from early development to approval and commercialization
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
April 11, 2024
Fosgonimeton counteracts mechanisms of amyloid-beta (Aβ)-driven toxicity and demonstrates neuroprotection in preclinical models of Alzheimer’s disease
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
April 03, 2024
Presentation to highlight therapeutic potential of Athira’s small molecules targeting the neurotrophic HGF system in neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease and...
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
March 08, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
February 22, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
February 08, 2024
Results demonstrate ATH-1105 is neuroprotective, preserves motor and nerve function and extends survival in preclinical models of ALS
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
January 08, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
January 03, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
December 12, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Sidoti Events, LLC's Virtual December Small-Cap Conference
December 05, 2023
Via
ACCESSWIRE
These biotechs targeting multiple neurodegenerative diseases
December 01, 2023
A growing number of up-and-coming biotech firms are demonstrating the value of expanding a drug's total addressable market.
Via
MarketBeat
Athira Pharma to Participate in Sidoti December Small Cap Investor Conference
November 29, 2023
Company Presentation to highlight novel therapeutic candidates targeting the HGF neurotrophic system in late-stage clinical development in neurodegenerative diseases, including Alzheimer’s disease
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND
November 28, 2023
Presentation to highlight preclinical data from ATH-1105, Athira’s potential treatment candidate for amyotrophic lateral sclerosis (ALS)
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s Disease
November 15, 2023
Data presented at Society for Neuroscience Annual Meeting 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates
November 09, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma to Participate in Jefferies London Healthcare Conference
November 08, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
October 05, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma to Participate in Upcoming October Conferences
September 28, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
September 19, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates
August 10, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer’s Disease
July 17, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.